Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rhythm Biosciences Ltd. ( (AU:RHY) ) has shared an announcement.
Rhythm Biosciences has secured National Association of Testing Authorities accreditation for its ColoSTAT blood-based colorectal cancer test within its ISO 15189:2022-certified Parkville laboratory. This recognition confirms that both the facility and the ColoSTAT assay meet internationally accepted standards for medical testing quality, competence, and result traceability.
With ColoSTAT now an accredited clinical laboratory service, Rhythm can begin offering the test to referring clinicians and patients as part of its commercial launch in Australia. The accreditation is also a key step toward pursuing Medicare Benefits Schedule reimbursement, which could support broader physician uptake and integration of ColoSTAT into routine colorectal cancer screening pathways.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian cancer diagnostics technology company focused on developing predictive, blood-based tests, with a key product being ColoSTAT, a colorectal cancer screening assay. The company operates an ISO 15189:2022-certified laboratory in Parkville, Victoria, and is targeting wider clinical adoption of its diagnostics across the Australian healthcare market.
Average Trading Volume: 1,044,865
Technical Sentiment Signal: Buy
Current Market Cap: A$62.56M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.